Identifying the relevant analytical methods to characterize adeno-associated viruses (AAVs) helps gene therapy developers determine product stability during formulation development. This provides a strong foundation for robust products and simplified distribution.
Join us to learn as Carina Rodenstein, Scientist at Leukocare, compares the analytical techniques used to study features of viral vectors that are crucial to capsid design and formulation development. Formulation development requires optimal resolution of analytics to investigate the stability-indicating parameters of viruses under different stresses. Based on the example of a non-enveloped AAV, Carina will demonstrate how to define relevant analytical methods for your specific needs.
In addition to the learning outcomes listed below, there will also be a Q+A session where you’ll be able to hear Carina answer questions asked by the audience.
Guest Presenter: Carina Rodenstein - Scientist at Leukocare
Who should attend?
- Pharmaceutical scientists with interest in viral vectors and analytics
- Scientists working in the development, manufacturing or formulation development of viral vectors especially AAV
What will you learn?
- Understand the analytical techniques for viral capsid count, percentage of full particles, particle size, potential aggregate formation, and capsid stability and infectivity
- Learn how to analyze specific characteristics of viral vectors, such as the amount of full capsids, capsid stability, and particle size distribution
- Learn about the stability-indicating potential of the analytical methods applied to AAV vector characterization during accelerated aging in a set of buffers.
- Understand the strengths and weaknesses of applying orthogonal techniques, focussing on formulation development for viral vectors.